We examined the efficacy and adverse events of continuous l-asparaginase administration in dogs with large cell lymphoma of presumedgastrointestinal (GI) origin. We retrospectively reviewed medical records of dogs with large cell lymphoma of presumed GI origin treated with continuous l-asparaginase administration from 2009 to 2018. We collected information on the signalment, lesion site, complete blood count, serum biochemical profile, diagnostic imaging findings, cytological and histopathological findings, immunophenotype, l-asparaginase administration frequency, treatment response, adverse events, rescue protocol, and patient outcomes. Clinical outcomes were assessed using medical records or by contacting the owner or referring veterinarian. Thirty-two dogs with large cell lymphoma of presumed GI origin received weekly l-asparaginase administration. The median number of l-asparaginase injections was seven (range: 1–30). Although two of the 32 dogs had GI toxicity of grade 3 or higher, none developed a hypersensitivity reaction. The response rate based on ultrasonographic findings was 18/32 (56%) and that based on clinical signs was 30/32 (94%). The median overall progression-free survival was 50 days (range: 2–214 days), and median overall survival was 147 days (range: 2–482 days). Adverse events associated with continuous l-asparaginase administration were rare. Clinical signs at diagnosis improved in most cases. Based on these results, continuous l-asparaginase administration appears to be a reasonable treatment option for dogs with large cell lymphoma of presumed GI origin.

中文翻译：

---

持续给予 l-天冬酰胺酶治疗推测为胃肠道起源的犬大细胞淋巴瘤的疗效和不良事件

我们检查了在推测为胃肠道 (GI) 起源的大细胞淋巴瘤犬中持续给予l-天冬酰胺酶的疗效和不良事件。我们回顾性回顾了 2009 年至 2018 年连续给予 L-天冬酰胺酶治疗的推测为胃肠道来源的大细胞淋巴瘤的狗的医疗记录。我们收集了有关信号、病变部位、全血细胞计数、血清生化特征、诊断成像结果、细胞学的信息。和组织病理学发现、免疫表型、l-天冬酰胺酶给药频率、治疗反应、不良事件、救援方案和患者结果。使用医疗记录或通过联系所有者或转诊兽医评估临床结果。32 只推测为胃肠道起源的大细胞淋巴瘤的狗每周接受l-天冬酰胺酶给药。l的中位数-天冬酰胺酶注射剂为七次（范围：1-30）。尽管 32 只狗中有 2 只具有 3 级或更高的胃肠道毒性，但没有一只狗出现过敏反应。基于超声检查结果的缓解率为 18/32 (56%)，基于临床症状的缓解率为 30/32 (94%)。中位总无进展生存期为 50 天（范围：2-214 天），中位总生存期为 147 天（范围：2-482 天）。与持续 L-天冬酰胺酶给药相关的不良事件很少见。在大多数情况下，诊断时的临床症状有所改善。基于这些结果，对于推测为胃肠道起源的大细胞淋巴瘤的狗，持续给予L-天冬酰胺酶似乎是一种合理的治疗选择。